anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Vitamin D status has been involved with coronavirus disease 19 (COVID-19) severity. This may be mediated by vitamin D metabolism regulatory genes. Of interest is the vitamin D receptor (VDR) gene, which has been previously associated with other inflammatory and respiratory diseases. In order to investigate the role of VDR gene polymorphisms in COVID-19 severity and outcome, a total of 292 COVID-19 patients were classified according to severity in moderate (n = 56), severe (n = 89) and critical (n = 147) and, according to outcome in survivor (n = 163) and deceased (n = 129), and analysed for FokI and TaqI VDR gene polymorphisms by polymerase chain reaction-based restriction enzyme digestion. The FokI and TaqI single nucleotide polymorphisms (SNPs) were not associated with COVID-19 severity or mortality individually but when analysed by haplotype, TC was associated with an increased risk of presenting critical COVID-19. Additionally, FokI CT genotype was more frequent in COVID-19 patients with hypertension, and T allele carriers presented higher aspartate aminotransferase levels. Our results suggest a relationship between VDR FokI and TaqI SNPs and COVID-19 severity in Mexican population. Although there are some previous reports of VDR polymorphisms in COVID-19, this represents the first report in Latin American population. Further studies on other populations are encouraged.
An extract of Iris root is disclosed. The iris root extract is obtained from iris root material by selective extraction and is optionally enriched with (a) a phytochemical melanogenesis stimulator or (B) a phytochemical melanogenesis inhibitor. The phytochemical melanogenesis stimulator (a) comprises germanaism B, and the phytochemical melanogenesis inhibitor (B) comprises irifloreal and/or iripallidal. Also provided is a method of preparing an iris root extract composition, and comprising selectively extracting iris root material to obtain at least one iris root extract. Also provided are functional compositions comprising the iris root extract. The functional composition is suitable for administration to a subject by topical application and exhibits activity associated with skin pigmentation.
Acute myocardial infarction (AMI) represents a critical cardiovascular condition necessitating rapid and precise diagnostic strategies. This study investigates the diagnostic implications of genes involved in copper metabolism homeostasis in AMI. We identified genes related to copper metabolism and AMI from Genecards and GEO databases, conducting differential gene analysis via R software. Gene function was annotated through Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses, while the STRING database facilitated key gene identification via topological analysis. The diagnostic value of these genes, particularly cytokine signaling 3 (SOCS3), was assessed using ROC curve analysis. SOCS3 expression was validated using in-vitro and in-vivo models, including cardiomyocyte hypoxia/reoxygenation (H/R) and rat myocardial infarction (MI) model. Further, we examined the effects of SOCS3 knockout on cell proliferation, apoptosis, and myocardial infarction severity. 77 genes were identified, with 73 showing upregulation and 4 downregulation. These genes mainly participated in pathways related to cytokine activation, inflammation regulation, and lipid metabolism. Network analysis highlighted 10 key genes, with SOCS3 exhibiting significant diagnostic potential (AUC > 0.9). Validation experiments confirmed SOCS3 overexpression in disease models, with its knockout leading to decreased apoptosis, reduced infarct size, and improved cardiac function. This study highlights the diagnostic relevance of genes associated with copper metabolism, particularly SOCS3, in AMI. These findings offer novel insights into the molecular mechanisms of AMI, supporting the development of targeted diagnostic and therapeutic strategies.
The observed incidence of antidrug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of antidrug antibodies (ADA) in the trials described below with the incidence of antidrug antibodies in other trials, including those of cipaglucosidase alfa-atga or of other cipaglucosidase alfa products.

Table 4 presents the incidence of ADA and neutralizing antibodies against cipaglucosidase alfa-atga in adult patients with LOPD treated with POMBILITI in combination with Opfolda (who previously received U.S.-approved alglucosidase alfa or a non-U.S.-approved alglucosidase alfa product) during the 52-week treatment period in Trial 1 [see Clinical Studies (14)].

Antibodies against cipaglucosidase alfa-atga (anti-cipaglucosidase alfa-atga antibodies) were cross-reactive to alglucosidase alfa.

Patients who had an IAR post‑treatment were tested for anti-cipaglucosidase alfa-atga IgE antibodies after the occurrence of the IAR. For ERT‑experienced patients, 25% of POMBILITI‑treated patients had IARs, with 1 patient having positive results for anti‑cipaglucosidase alfa-atga IgE antibodies [see Adverse Reactions (6.1)]. Overall, there was no clear trend in IAR occurrence with the development of anti-cipaglucosidase alfa-atga IgE antibodies.

There was no identified clinically significant effect of ADA on pharmacokinetics or pharmacodynamics of POMBILITI in combination with Opfolda over the treatment duration of 52 weeks. Because of the small number of patients with negative ADA, the effect of ADA on the effectiveness of POMBILITI in combination with Opfolda is unknown.

Table 4. Incidence of Anti-Cipaglucosidase alfa-atga IgG Antibodies in ERT-experienced POMBILITI-treated Adult Patients with LOPD (Trial 1)*
The invention discloses a medicine composition for treating xerophthalmia. The medicine composition is a preparation prepared from the following crude drugs in weight ratio: 12-18 parts of rhizoma polygonati, 8-12 parts of radix glehniae, 8-12 parts of medlar and 8-12 parts of chrysanthemum. According to the medicine composition disclosed by the invention, the rhizoma polygonati, the radix glehniae, the medlar and the chrysanthemum are reasonably combined, and thus, symptoms, such as dryness, foreign body sensation and hyperemia of bulbar conjunctiva of eyes, can be obviously improved. The medicine composition can be effectively used for treating xerophthalmia caused by video terminals, middle-aged and elderly xerophthalmia or diabetic xerophthalmia. Moreover, the clinical effect of the medicine composition is obviously superior to that of the Western medicine Tears Natural II group and the traditional Chinese medical science acupuncture group. The medicine composition is high in safety and good economic benefit, and a new medicine selection is provided for clinically treating the xerophthalmia.
<P>PROBLEM TO BE SOLVED: To provide a technique for keeping the initial state of the skin finished with a makeup cosmetic product for a long period.  <P>SOLUTION: The foundation cosmetic product contains (1) an aluminum-zinc intercalate pillared clay and (2) a clay mineral modified with an organic material. The clay mineral modified with an organic material is preferably hectorite modified with dimethyl distearyl ammonium chloride. The cosmetic product preferably contains a polyether-modified methylsiloxane preferably having a crosslinked structure. The cosmetic product is preferably a foundation cosmetic, more preferably a foundation cosmetic for a hydrophobic makeup cosmetic product.  <P>COPYRIGHT: (C)2007,JPO&INPIT
The primary purpose of this study is to determine whether biological sex influences the peak cardiac output response to 12 weeks of sprint interval exercise training. Peak cardiac output will be determined non-invasively using an inert gas rebreathing technique. Each session of sprint interval exercise training will involve a 10-minute period of cycling on a stationary ergometer. The protocol will consist of a two-minute warm-up; three, 20-second 'all out' efforts that are separated by two minutes of recovery; and a three-minute cool down. Three sessions of training will be performed each week for a total of 12 weeks. Groups of male and female participants will be recruited and tested using best practice guidelines for sex-based comparisons of exercise responses. The study will advance knowledge regarding the potential for biological sex to influence the cardiovascular response to brief vigorous cycle exercise training.
PROBLEM TO BE SOLVED: To provide a die capable of easily releasing a molded rod-like cosmetic and obtaining the high-quality rod-like cosmetic rarely stuck with a mold releasing agent on the surface by forming the die with a resin material containing the mold releasing agent. SOLUTION: Resin pellets are put into a heated kneading tube, and a screw is rotated to completely melt them. A mold releasing agent is added, and the mixture is kneaded into a melted state. The melted resin containing the mold releasing agent is filled into a die. The die is disassembled into an outer die and an inner die after the melted resin is hardened. A resin die is fitted to a center disk 5 of a lipstick container. The large-diameter section 1 of the resin die is coupled with the end section of the center dish 5. A melted cosmetic is filled into the resin die from an opening section disposed at the bottom section of the center dish 5. The resin die is removed after the cosmetic is solidified. When the melted high-temperature cosmetic is filled, the mold releasing agent is eluted from the inner face of the resin die.  The same mold releasing effect is exerted as the case that the mold releasing agent is applied on the inner face of the resin die in advance.
Patients with repaired Tetralogy of Fallot or Fallot-like pathology (double-outlet right ventricle Fallot type, tetralogy of Fallot with pulmonary atresia), evaluated at least 1 year after the last surgical or percutaneous procedure, will be recruited by regional reference centers for congenital heart disease. Additional inclusion criteria are age \> 10 years, height \> 140 cm, New York Heart Association class I or II. Right ventricular function will be assessed at baseline and peak stress with variations (rest and peak stress) of tricuspid annular plane systolic excursion. A sample size of about 250 patients is required to detect a significant stress-induced increase in tricuspid annular plane systolic excursion.
The incidence of adrenal cysts is 0.06% and only 9% of these are true mesothelial cysts. Here, we present a case of a true mesothelial cyst together with a review of the literature. A female in her 30s presented to the surgical outpatient department complaining of right flank pain. Her contrast-enhanced CT scan revealed a 7.5×6.5×4.5 cm right adrenal gland cyst. The patient underwent a laparoscopic right adrenalectomy. Immunohistopathology revealed the cyst to be mesothelial in nature. The majority of true mesothelial adrenal cysts are benign, unilateral and more common in women. Any adrenal cyst diagnosed as a functional lesion or one that may be malignant or with a diameter of 5 cm or greater requires surgical care whereas smaller lesions can be managed conservatively. Laparoscopic adrenalectomy for an adrenal cyst of diameter greater than 6 cm is a safe and feasible procedure in expert hands if there is no invasion of surrounding tissue.
This cohort includes individuals with asthma and a control group from the Finnish biobank database, consisting of 20,629 cases of asthma and 135,449 controls. Genetic data were analyzed to examine causal associations with allergic rhinitis.
BACKGROUNDS: Fat infiltration of skeletal muscle has been recognized as a common feature of many degenerative muscle disorders. Retinol binding protein 4 (RBP4) is an adipokine that has been demonstrated to be correlated with the presence and severity of sarcopenia in the elderly. However, the exact role and the underlying mechanism of RBP4 in muscle atrophy remains unclear.
METHODS: Denervation-induced muscle atrophy model was constructed in wild-type and RBP4 knockout mice. To modify the expression of RBP4, mice were received intramuscular injection of retinol-free RBP4 (apo-RBP4), retinol-bound RBP4 (holo-RBP4) or oral gavage of RBP4 inhibitor A1120. Holo-RBP4-stimulated C2C12 myotubes were treated with siRNAs or specific inhibitors targeting signalling receptor and transporter of retinol 6 (STRA6)/Janus kinase 2 (JAK2)/Signal transducer and activator of transcription 3 (STAT3) pathway. Fat accumulation, myofibre cross-sectional area, myotube diameter and the expression of muscle atrophy markers and myogenesis markers were analysed.
RESULTS: The expression levels of RBP4 in skeletal muscles were significantly up-regulated more than 2-fold from 7 days and sustained for 28 days after denervation. Immunofluorescence analysis indicated that increased RBP4 was localized in the infiltrated fatty region in denervated skeletal muscles. Knockout of RBP4 alleviated denervation-induced fatty infiltration and muscle atrophy together with decreased expression of atrophy marker Atrogin-1 and MuRF1 as well as increased expression of myogenesis regulators MyoD and MyoG. By contrast, injection of retinol-bound holo-RBP4 aggregated denervation-induced ectopic fat accumulation and muscle atrophy. Consistently, holo-RBP4 stimulation also had a dose-dependent effect on the reduction of C2C12 myotube diameter and myofibre cross-sectional area, as well as on the increase of Atrogin-1and MuRF1 expression and decrease of MyoD and MyoG expression. Mechanistically, holo-RBP4 treatment increased the expression of its membrane receptor STRA6 (>3-fold) and promoted the phosphorylation of downstream JAK2 and STAT3. Inhibition of STRA6/JAK2/STAT3 pathway either by specific siRNAs or inhibitors could decrease the expression of Atrogin-1 and MuRF1 (>50%) and decrease the expression of MyoD and MyoG (>3-fold) in holo-RBP4-treated C2C12 myotube. RBP4 specific pharmacological antagonist A1120 significantly inhibited the activation of STRA6/JAK2/STAT3 pathway, ameliorated ectopic fat infiltration and protected against denervation-induced muscle atrophy (30% increased myofibre cross-sectional area) in mice.
CONCLUSIONS: In conclusion, our data reveal that RBP4 promotes fat infiltration and muscle atrophy through a STRA6-dependent and JAK2/STAT3 pathway-mediated mechanism in denervated skeletal muscle. Our results suggest that lowering RBP4 levels might serve as a promising therapeutic approach for prevention and treatment of muscle atrophy.
PURPOSE: To assess the value of routine mid-trimester fetal ultrasound scans in detecting FCs, as well as the related ultrasound and clinical follow-up outcomes.
METHODS: A retrospective analysis was conducted on 1064 fetuses who underwent standardized ultrasound screening during the mid-trimester. During the examination, high-frequency ultrasound was used to examine the fetal spine. Different frequency ultrasound probes were used to compare and analyze the detection rates of FCs. We conducted follow-up ultrasound observations on all FCs and conducted long-term follow-up observations in terms of the motor function of the children after birth.
RESULTS: Among 1064 fetuses detected by ultrasound, a total of 910 fetuses were completely evaluated using high-frequency and low-frequency ultrasound, and 24 FCs were found. In all 24 cases of FCs, 7 cases were detected using low-frequency ultrasound, while high-frequency ultrasound detected all cases. There was a significant difference in the detection rates between the two groups (χ2 = 26.323, P = 0.000). Of all the 24 FCs, 21 cysts disappeared spontaneously (87.5%); one fetus was induced for abortion due to a concurrent cleft lip; after multiple ultrasound examinations, it was found that the cyst persisted in one fetus; one case was not followed up by ultrasound. There was no statistically significant difference in the start of sitting and crawling time between the control group and the FCs group.
CONCLUSION: Routine mid-trimester fetal ultrasound scan detect FCs, particularly when high-frequency ultrasound probes were routinely applied. Most FCs detected by prenatal ultrasound spontaneously disappear and have no impact on the motor function of the fetus after birth (with the conus medullaris located at or above the L3 level). The shortest time interval from the detection to the disappearance of the cyst was 11 days.
PRP is a portion of the plasma fraction of autologous blood, having a platelet concentration above baseline values. PRP is made by centrifugation of whole blood (drawn from a peripheral vein and stored in an acid citrate dextrose solution A (ACD-A) anticoagulant), which separates the various components of blood by their specific weight and increases the concentration of platelets.

Platelets are a rich source of the complex group of proteins called growth factors (GFs) involved in natural wound healing and in regeneration of injured tissues. GFs are active signals for attracting stem cells into the site of injury and triggering proliferation of these cells. PRP limit inflammation, interacting with macrophages to improve tissue healing and regeneration, promote new capillary growth, and accelerate epithelialization. Platelets in PRP also play a role in host defense mechanism at the wound site by producing signaling proteins that attract macrophages; PRP also may contain a small number of leukocytes that synthesize interleukins as part of a non-specific immune response. Previous studies of PRP have demonstrated antimicrobial activity against Escherichia coli, Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus, Candida albicans, and Cryptococcus neoforma. So, PRP is effective in soft tissue healing, having no side effect and showed excellent healing score in skin wound healing.
The method involves collecting medication data in relation to each of the patients. All or selected medicaments are prepared on the basis of the collected medication data. The prepared medicaments are automatically placed for each of the patient in the medicament box (12) as per the medication data. The filled or to be filled medicament box is designated on the basis of the identifying device with control data for correction and verification correlation to each of the patients. The identifying device is a radio frequency identification chip (14). Independent claims are also included for the following: (1) a system for supplying medicaments in a medicament box (2) an assembly apparatus for inserting medicaments into a medicament box (3) a computer program product.
FIELD: medicine, endocrinology, cardiology. SUBSTANCE: the method deals with treating children with type I diabetes mellitus. For this purpose, at initial stages of cardiomyopathy one should introduce tanacane per 80-120 mg/d by 3-mo-long courses. The method provides prevention for cardiac lesion progression in case of diabetes and improves functional possibilities due to normalization of diastolic function of left ventricle. EFFECT: higher efficiency. 2 tbl
Specified estimated glomerular filtration rate (eGFR) range according to different CKD etiologies. For glomerular nephrology patients, the eGFR should be ≥15 ml/minute per 1.73m(2). For diabetic nephrology patients, the defining eligibility was 15 ml/minute per 1.73m(2)≤eGFR \<60 ml/minute per 1.73m(2) or eGFR≥ 60 ml/minute per 1.73m(2) with "nephrotic range" proteinuria, which is defined as 24-hour urinary protein ≥3.5 g or urinary albumin creatinine ratio ≥2 000 mg/g or corresponding values of urine dipstick test or urinary protein creatinine ratio. For non-glomerular nephrology and non-diabetic nephrology patients, 15 ml/minute per 1.73m(2) ≤eGFR\<60 ml/minute per 1.73m(2) is set for enrollment.
Angiogenesis is a physiological process of forming new blood vessels that has pathological importance in seemingly unrelated illnesses like cancer, diabetes, and various inflammatory diseases. Treatment targeting angiogenesis has shown promise for these types of diseases, but current anti-angiogenic agents have critical limitations in delivery and side-effects. This necessitates exploration of alternative approaches like biomolecule-based drugs. Proteins, lipids, and oligonucleotides have recently become popular in biomedicine, specifically as biocompatible components of therapeutic drugs. Their excellent bioavailability and potential bioactive and immunogenic properties make them prime candidates for drug discovery or drug delivery systems. Lipid-based liposomes have become standard vehicles for targeted nanoparticle (NP) delivery, while protein and nucleotide NPs show promise for environment-sensitive delivery as smart NPs. Their therapeutic applications have initially been hampered by short circulation times and difficulty of fabrication but recent developments in nanofabrication and NP engineering have found ways to circumvent these disadvantages, vastly improving the practicality of biomolecular NPs. In this review, we are going to briefly discuss how biomolecule-based NPs have improved anti-angiogenesis-based therapy.
The study will be a three-arm, randomized, double-blind, placebo-controlled trial. The study population will include 60 males and females, ages 19 and older, who report chronic problems with insomnia at least three times per week for at least three months and have a diagnosis of co-morbid MDD. Eligible participants will complete a urine screen for drugs of abuse including opioids, cannabis, benzodiazepines and amphetamines before treatment randomization. Participants with a positive screen for any of these drugs of abuse will be excluded from the study. If the drug screen is negative, the principal investigator will assess patient health history and perform a physical examination. All study participants must be able to fully understand the study procedures and must sign a research ethics board (REB)-approved informed consent before study entry. A neuropsychological battery will be used to assess cognitive function in the domains of attention, verbal memory, psychomotor functioning, and executive functioning at baseline and at the end of the 4-week treatment in order to examine possible cognitive benefits or side effects from the treatment. These cognitive domains were chosen because these domains are known to be negatively affected by chronic insomnia and by cannabis use. Patients will also complete a series of clinician-rated and self-reported questionnaires.

During the 4-week treatment period, participants will be instructed to start treatment with a single, dose of oil at bedtime. Each dose will have either 50 mg/ml CBD and 2 mg/ml THC (High CBD arm; MLP-001) or 10 mg/ml CBD and 2 mg/ml THC (Low CBD arm; MLP-002). Non-responding study participants will add 1 additional dose to their respective treatment after 2 weeks if a higher dosage is needed based on an Insomnia Severity Index (ISI) reduction of \>8 points and tolerability (side effects). Responding participants will continue with 1 dose of their treatment after 2 weeks. This dose range is based on previous studies showing that the effective dosage of THC to improve sleep ranged, on average, between 5 and 15 mg daily.
The invention relates to a controlled release composition comprising acylanilide, and preferably bicalutamide, for use, in particular, in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analogue for the treatment of stage D2 metastatic carcinoma of the prostate. The controlled release composition comprises an immediate release component and a modified release component or formulation. The immediate release component comprises a first population of bicalutamide. The modified release formulation preferably comprises a second population of acylanilide bicalutamide, and a controlled release constituent. The controlled release formulation is preferably in the form of an erodable formulation, a diffusion controlled formulation or an osmotic controlled formulation. The combination of the immediate release and modified release components in operation deliver the active ingredient in a pulsed or bi-modal manner.